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Mapping of antigenic peptide sequences from proteins of relevant pathogens recognized by T helper (Th) and by cytolytic T
lymphocytes (CTL) is crucial for vaccine development. In fact, mapping of T-cell epitopes provides useful information for the
design of peptide-based vaccines and of peptide libraries to monitor speciﬁc cellular immunity in protected individuals, patients
and vaccinees. Nevertheless, epitope mapping is a challenging task. In fact, large panels of overlapping peptides need to be
tested with lymphocytes to identify the sequences that induce a T-cell response. Since numerous peptide panels from antigenic
proteins are to be screened, lymphocytes available from human subjects are a limiting factor. To overcome this limitation, high
throughput (HTP) approaches based on miniaturization and automation of T-cell assays are needed. Here we consider the most
recent applications of the HTP approach to T epitope mapping. The alternative or complementary use of in silico prediction and
experimental epitope deﬁnition is discussed in the context of the recent literature. The currently used methods are described with
special reference to the possibility of applying the HTP concept to make epitope mapping an easier procedure in terms of time,
w o r k l o a d ,r e a g e n t s ,c e l l sa n do v e r a l lc o s t .
1.Introduction
Mapping of T epitopes on protein antigens derived from
relevant pathogens implies the identiﬁcation of amino acid
sequences that are recognized by CD4 or CD8 T cells.
The term “epitope” is frequently used interchangeably for
“immunodominant peptide”. For the sake of precision,
though, epitope should refer to the shortest sequence
that maintains stimulatory capacity for T cells, while the
immunodominant peptide can be of any length and its
deletions allow identiﬁcation of the corresponding epitope.
Epitope mapping is important in vaccine development
[1, 2] for several reasons: (1) epitopes are presented in
the context of one or few MHC alleles [3–7] and in some
instances they are promiscuous (i.e. presented by more
alleles) [8–11] or universal (i.e. presented by most of the
alleles) [12–16]; (2) epitopes represent the antigenic portion
ofaproteinandthusthenonantigenicregionscanbedeleted;
(3) epitopes restricted to diﬀerent alleles can be collected
to obtain selected peptide libraries that are recognized by
the majority of the immune population [17, 18], thereby
providingavaluablediagnostictool[19–27];(4)epitopescan
be selected to construct peptide-based vaccines.
Peptides derived from HIV and restricted to human
DR alleles were used as pools to prime mice to induce
vigorous CD4 responses [28]. Peptides as strings of beads
were produced as a recombinant protein to express and
immunize against P. falciparum epitopes [29]. As additional
examples, peptides as strings of beads have also been used
as immunogens speciﬁc for HIV [30–32], for mycobacyteria
[33], for tumor-associated viral antigens [34], for LCMV
[35] and for immunodominant epitopes of ﬁve diﬀerent
viruses [36]. In addition, selected peptide fragments can be
assembled as mosaic proteins to produce polyvalent vaccines
for coverage of potential T-cell epitopes in HIV variants.
[37].
In fact, epitope variability in pathogens like HIV [38]i s
instrumental for development of escape mutants [39]a n d
represents the greatest challenge for the immune system that
must deal with these mutations.2 Journal of Biomedicine and Biotechnology
The converse situation, deﬁned as deimmunization,
permits selective removal by protein re-engineering of
immunogenic epitopes identiﬁed on proteins to be used as
therapeutic agents. In this case, in fact, potential antigenicity
must be avoided to improve clinical eﬀectiveness. This
innovative possibility has been described in detail [40, 41].
In the present review we mention the predictive and
experimental systems that can be used for T-cell epitope
mapping. Since the experimental work requires functional
T lymphocytes, the number of available cells is a limiting
factor with current methods [42]. Furthermore, the time to
perform the assays, the cost of reagents and the workload
are additional limiting factors in epitope mapping. Peptide
synthesisinparticularhasaremarkableimpactwhenepitope
mapping is budgeted. Therefore, in addition to in silico
epitope prediction, as discussed later, any miniaturization
that reduces the amount of required peptides is helpful. The
possibilityofusingahighthroughput(HTP)approachbased
on assay miniaturization and automation to test extended
peptide panels will be dealt with in more detail. The HTP
approach, in fact, permits reduction of the number of cells
to be tested, of the amount of tested peptides, of the cost
of reagents and of the workload referred to the information
that can be obtained. The HTP concept can be applied to
diﬀerenttechniquesthatcanbeautomatedandminiaturized,
as described later.
2. PredictiveModels of T-Cell Responses
Algorithmshavebeendevelopedtotestthepotentialcapacity
ofagivenpeptidetobindapredeterminedMHCallele.From
this information it can be assumed that a T-cell with such a
speciﬁcity can be present in the T-cell repertoire. Obviously,
speciﬁc T-cell are expected to be at very low frequency in
the speciﬁc na¨ ıve repertoire, while their frequency should be
much higher in a primed repertoire. As pointed out later,
this is probably the major diﬀerence between in silico and
in vitro epitope mapping: in the former case an assumption
is made while in the latter case an experimental approach
is taken that must take into account the na¨ ıve or memory
state of the speciﬁc repertoire that is being tested. Another
important point is that in silico screening is faster and
cheaper and certainly permits deletion of certain peptides
that have no MHC binding potential and thus can be
excluded from the list of potential candidates. Therefore, a
preliminary prediction may result in remarkable reduction
in the number of peptides to be synthesized and screened
against responding lymphocytes.
Predictive methods have been developed for human and
murine MHC alleles, including class I and class II molecules
[43–50]. A large scale validation study for CTL epitope
prediction has been recently published by comparing ﬁve
diﬀerent web-based tools [51]. Prediction of binding aﬃnity,
in addition to speciﬁcity, has been recently discussed in [43].
An updated description of predictive methods can be found
in the Los Alamos Database website [38]. This site has links
to tools for T epitope prediction based on MHC binding and
also on cleavage sites to predict antigenic peptide fragments
produced upon processing by the human proteasome [52,
53]. In fact, while MHC-peptide binding predictions con-
sider virtual peptides derived from arbitrary cleavage of the
protein sequence, anticipation of peptide fragments, that can
be actually produced by antigen processing and presenting
cells, can be of remarkable relevance also to reduce the
number of peptides to be examined as possible candidates
for immunogenicity. The combined predictions for TAP
binding peptides [54–56] and protein cleavage have been
modeled and considered for their potential applications,
in combination with MHC binding predictions. [57, 58].
The data generated by using prediction tools to deﬁne
MHC or TAP binding peptides have been collected in
a dedicated database [59]. This comprehensive database
includes a large collection of peptide sequences whose bind-
ing aﬃnities for MHC or TAP molecules have been assayed
experimentally.
The in silico methods based on MHC-peptide binding
prediction carry the obvious advantage that T epitopes can
be deﬁned independently of the primed or na¨ ıve status
of a subject. Several recent reviews have reported on this
subject and its integration with in vitro data [45, 60, 61].
Peptide binding to MHC class I for CD8 T-cell recognition
is certainly predictable with high conﬁdence, while MHC
class II binding algorithms have been recently criticized with
respect to reliability [62].
It should be stressed here that a higher integration
between in silico prediction and in vitro experiments [60]
should be considered, each one of the two approaches with
its pros and cons.
These aspects are considered in more detail in the
diﬀerent chapters.
MHCbindingisaprerequisiteforepitopepresentationto
speciﬁc T cells and thus prediction of MHC binding screens
for sequences that are potentially antigenic. Nevertheless,
MHCbinding,evenifexperimentallydeterminedtoappreci-
ateactualpeptide binding tosolidphaseMHC[63],doesnot
grant in itself that a T-cell with such a speciﬁcity is present
indeed in the T-cell repertoire. Therefore, experimental data
generated by in vitro work in which T cells are challenged
with peptides, are necessary to conﬁrm the prediction.
3. ExperimentalApproaches for T-Cell
Epitope Mapping andDataCollection
Several assays measure various features of T-cell activation
that follows antigen recognition, as described below in more
detail. Using diﬀerent methods, immunodominant peptides
have been identiﬁed on proteins of various pathogens. The
best example of an available database for experimentally
identiﬁed epitopes recognized by CD4 and CD8 T-cell s is
represented by the Los Alamos National Laboratory database
[38] that provides updated information on HIV T epitopes.
Another exhaustive database is represented by the Immune
Epitope Data Base (IEDB, http://tools.immuneepitope.org)
[64–66], in which an accurate description of the individual
contributionsisgiven.Thisdatabaseisfedwithexperimental
data obtained by literature searches or by voluntary sub-
missions, with an accurate description of methods used for
epitope identiﬁcation.Journal of Biomedicine and Biotechnology 3
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Figure 1: Conventional layout of peptide panels for T epitope mapping. In this example of a panel of 100 peptides, peptides can be tested
individually in one step or as pools in two steps. Peptide 7 in bold represents the immunodominant peptide. Response to a positive pool can
be further deconvoluted by testing the individual peptides encompassed by the stimulatory pool. The one step approach is simpler, but it
requires more cells. The two-step approach requires fewer cells, but cells are needed at two diﬀerent times. Thus, the cases in which a small
fraction of pools are positive can take advantage of this approach, while in the worst case, in which the majority of the pools are positive and
need to be individually deconvoluted, the two-step approach provides no signiﬁcant advantage.
4. Peptide Layoutfor High Throughput
TEpitope Mapping
OneaspectoftheTepitopemappingmethodologiesisrepre-
sented by the use of synthetic peptides. The straightforward
approach is to produce a complete panel of peptides, with
a given length and a predetermined overlapping sequence,
that encompass the candidate protein. This comprehensive
procedure, though, is limited by the cost of peptide synthesis
and thus peptide panels can be restricted by deleting
those peptides that have been predicted as non binders
using in silico screening. A detailed discussion on synthetic
peptides to be used for epitope mapping has been published
[67].
An epitope with a sequence spanning two sequential
peptides would be missed if it is not encompassed by the
overlapping sequence. The ideal peptide scan should be with
one amino acid progression (sequential peptides). Apart
from increased cost, this would be possible when mapping
epitopes recognized by antibodies, that are available, in
practice, at unlimited amount from diluted serum and that
can be tested on microarray formats. For cellular assays that
detect T-cell immunity, available PBMC are an incumbent
limitation. In order to induce CTL and Th responses, 15–
18mer peptides overlapping by 11 amino acid residues are
commonly used. This peptide size is selected so to have
potential binding capacity to MHC class I and class II. In
order to avoid the need for a CD4 peptide panel and a CD8
peptide panel, a compromise can be reached as described
in an extensive study [68] using peptides derived from the
immunodominant pp65 protein of cytomegalovirus. Even
if it was conﬁrmed that 9mers are optimal stimulators
for CD8 responses, it was clearly shown that 15mers can
also be used to detect CTL activation. This paper also
presents the conundrum of which should be the optimal
overlap between contiguous peptides in order not to miss
a stimulatory epitope. It is concluded that in the case of
15mers overlapping by 11 residues, each possible 9mer is
present in two 15mers, except for the one with a central
location, that is, present only once in the middle of the
15mer. To obviate this limit and to have all 9mers, including
the central ones, represented in at least two 15mers, peptides
should overlap by 3 residues. This implies a 25% increase
in the number of peptides. Therefore, also in this case
a compromise must be accepted between number/cost of
synthesized peptides and conﬁdence that no epitopes are
present in suboptimal conﬁgurations (i.e. at the extreme
N- or C-terminus of longer peptides). Another point to be
considered is the calculated risk of missing some epitopes
when overlapping instead of sequential peptides are used. It
is reasonable to say that it is acceptable to miss some epitopes
when dealing with large, highly antigenic proteins on which
numerous epitopes are expected, as in the case of proteins
derived from pathogens. On the contrary, in the case of small
proteins or antigens on which a few antigenic epitopes are
predicted, as in the case of tumor antigens, the search should
be more thorough.
If sequential peptides from panels are individually tested
(Figure 1), this results in the use of large numbers of lym-
phocytes for screening, independently of the method in use
(see following paragraphs). Alternatively, discrete pools of
peptides can be used for preliminary screening, followed by
deconvolution based on testing individual peptides present
in the stimulatory pools (Figure 1).4 Journal of Biomedicine and Biotechnology
Epitope mapping with peptide matrices
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Figure 2: Epitope mapping with peptide matrices. As an example, a panel of 100 peptides is considered. Instead of being tested individually,
peptides can be arranged in a matrix of 10 vertical pools (V1-V10) and 10 horizontal pools (H11-H20). The left panel depicts an
unambiguous identiﬁcation. In fact, if peptide 44 only is antigenic, pools V4 and H15 are stimulatory (arrows), thereby pointing at the
relevant peptide at the intersection. The right panel depicts an ambiguous identiﬁcation. In fact, if V2-V7 and H12-H7 pools are stimulatory
(arrows), all peptides in the shaded area can be antigenic, but the same result would be obtained if only peptides 12,23,34,45,56,67 were
antigenic. Therefore, the intersections of the stimulatory pools could indicate from a minimum of 6 to a maximum of 36 antigenic
peptides. This ambiguity would require an additional deconvolution step in which individual peptides identiﬁed by the intersection area
are individually tested.
I no r d e rt os a v eo nc e l l s ,p e p t i d em a t r i c e sh a v eb e e n
introduced [69, 70]. In this case, horizontal and vertical
peptide pools are assembled as shown in Figure 2.I n
this example, 20 pools are screened instead of testing
100 individual peptides. The intersection resulting from
response to one vertical and one horizontal pool reveal
the antigenic peptide. This is a convenient approach in
principle. In fact, unambiguous deﬁnition of the antigenic
peptide results at the intersection (left panel). Nevertheless,
in case more peptides are antigenic, the intersections can be
ambiguous (right panel) and a second deconvolution step
withindividualcandidatepeptidespresentinthestimulatory
pools is needed as detailed in the ﬁgure legend. In the
layout of this type of experiments, two types of peptide
containingplatesshouldbedesigned:theﬁrstonecontaining
the peptides as pools or in a matrix format, the second one
containing the full peptide panel. The second deconvolution
step can be run by seeding lymphocytes only in the wells
that contain peptides of stimulatory pools, rather than
preparinganewplateeachtimewiththeambiguouspeptides
contained in the stimulatory pools. This can reduce errors
and labour. Handling of large peptide panels can beneﬁt
from automated dispensers that use individual 96 or 384
channels for distribution from masterplates into secondary
replica plates.
Conventional peptide synthesis on mg scale provides
more material than actually needed. In fact, peptides are
currently used at 0.1–10ug/mL in culture. Miniaturized
peptide synthesis on pins [71–73]o ro np a p e rs p o t s[ 74,
75] permits a less expensive peptide synthesis. In addition,
microsynthesis in 96 well plate formats permits an easier
transfer of peptides to 96 well or to 384 well plates,
thereby abating the risk of positional errors or cross-
contaminations.
Overlapping peptides have also been applied on microar-
ray slides for antibody epitope mapping [76], but this
approach is not applicable at the present time to T epitope
mapping with functional assays. In fact, there is no evidence
that solid phase peptides can be captured by membrane
MHC and pulse APC for presentation to speciﬁc T cells.
Furthermore, at least one speciﬁc T-cell should be present
in the microarea of one peptide spot and this depends
on the frequency of speciﬁc T cells, as discussed in a
later paragraph. Biotechnological developments in this ﬁeld
are desirable, even though it should be noted that the
microarray slide approach has already been used with MHC-
peptide complexes to retain and stimulate speciﬁc T cells, as
described later.
When the immunodominant protein of a given pathogen
is not known, conventional overlapping peptides panels can-
not be designed. Therefore, combinatorial peptide libraries
consisting of 10-mer mixtures containing every possible
combination of residues with only one ﬁxed position could
reveal the unknown epitopes [77–79].Journal of Biomedicine and Biotechnology 5
5. CurrentMethods for T Epitope Mapping
Once peptide panels in diﬀerent formats have been pro-
duced, T cells can be tested with diﬀerent methods to deter-
mine the stimulatory immunodominant peptides. Methods
to detect T-cell responses can be deﬁned as dynamic or static
[42], depending on whether a T-cell function is detected or
not. Most of the assays reveal a functional T-cell response
as upregulation of activation markers, cytokine synthesis,
proliferation, cytolytic, and helper function. Only MHC-
peptide multimers (MM) can be used independently of T-
cell functions. These ﬂuorescent reagents, in fact, bind and
label the speciﬁc T-cell receptors by simulating an antigen
presenting cell that displays an MHC-peptide complex.
All functional assays require also an intact APC function.
Therefore, optimized culture conditions are needed, in
particular to provide all speciﬁc T cells a chance to interact
with an APC. This means that cell density (cells versus
surface) is more important than cell concentration (cells
versus volume). This is crucial in order not to underesti-
mate responses, particularly if the method reads the actual
frequency of speciﬁc T cells (e.g. ELIspot, ICS).
5.1. MHC-Peptide Multimers. Multimers constructed with
speciﬁcMHCclassIallelesandcarryingawell-deﬁnedMHC
binding peptide and a ﬂuorescent tag [80] are simple to use,
require no culture steps and are revealed by ﬂow cytometric
analysis. Additional phenotypic and functional markers can
be simultaneous identiﬁed on the multimer (MM) binding
cells [81] .C e l l sa r en o ts a c r i ﬁ c e da n dt h u sc a nb ef u r t h e r
cultured or even used for in vivo reinfusion for adoptive
immunoreconstitution [82]. Besides these advantages, major
limitations are represented by the fact that puriﬁed MHC
class I molecules are available for a limited number of
alleles and by the fact that the antigenic peptide(s) need
to be known in advance, as a result of preliminary epitope
mapping. In order to apply MM to epitope mapping, a novel
approachhasbeenproposed[83]basedonreversiblebinding
of MHC and peptide. Here, the ﬁrst peptide contains a UV
cleavable site that results in its dissociation from MHC once
exposed to UV light. If a second peptide with the same
MHC binding capacity is present, it can replace the cleavable
peptide and generate a new MM with a diﬀerent speciﬁcity
(i.e. recognized by another T-cell receptor diﬀering for ﬁne
speciﬁcity but not for MHC restriction). If this process is
applied in microplates in which diﬀerent second peptides are
distributed in wells, a whole panel of MM can be constructed
for T-cell screening. This approach is appealing, but it is still
limited to a few MHC class I alleles and has not been proven
to function with MHC class II molecules.
Multimers with MHC class II alleles [84]a r en o ta s
broadly available as MHC class I multimers and technologi-
cal improvements are still under development [85].
5.2. Solid Phase MHC-Peptide Complexes. Spotting MHC
class I molecules on microarray slides, followed by binding
of immunodominant peptides, has been used to create solid
phase MHC-peptide complexes that can be recognized by
speciﬁc T cells. Lymphocytes bind and can be selectively
retained [86]. In addition, if the slide is also coated with an
anticytokine antibody, the cytokine secreted by speciﬁcally
activated T cells is captured as a spot and can be revealed by
immunoﬂuorescence with an appropriate scanner [87]. This
method could be applied for epitope mapping by deposition
of diﬀerent peptides on the MHC spots, but the complexity
of the manipulations and of the instrumentation required
make this approach not broadly applicable at the present
time.
5.3. Lymphoproliferation. The 3H-thymidine uptake assay
is sensitive and it has been extensively used in the past.
Nevertheless, it requires a radioactive reagent, no data on
cell phenotype, frequency or secreted cytokines are provided
and 3–5 culture days are needed. Finally, cells are sacriﬁced
and cannot be used any further. The classical format is the 96
well plate, with no possible extension to the 384 well format
because of the lack of appropriate harvesters on the market.
For these reasons, lymphoproliferation is loosing followers,
even though most of the initial epitope mapping data were
obtain with this technique. Lymphoproliferation resurged
when the CFSE dye dilution method was established. A
major advantage in this case is that the labeling dye is
diluted between daughter cells at each cell division and
thus ﬂuorescence quantitation can estimate the number of
duplications the cells went through. An accurate report with
methodological details has been recently published [88].
A comparison of proliferation versus ICS for T epitope
mapping has also been reported [89].
5.4. Activation Markers Induced on Speciﬁc T Cells. Several
activation markers have been used for identiﬁcation, enu-
meration, and selection of antigen speciﬁc CD4 and CD8
T cells. These markers for antigen activated T cells include
CD137 for detection of CD8 cells [90] and CD154 for
detection of CD4 cells [91]. Coexpression of CD25 and
CD134 also identiﬁes antigen speciﬁc CD4 T cells [92].
Therefore, the same markers can also be applied for epitope
mapping. The use of these markers is advantageous on
one side, as it combines functional activity with phenotypic
parameters, but it may be cumberson for HTP epitope
mapping.
5.5. ELIspot. T cells that secrete a given cytokine (IFNg
most of the times) as a consequence of antigen recognition
on APC can be detected by ELIspot. In this technique,
originally developed to detect antibody secreting B cells [93],
lymphocyte cultures are performed in 96 well plates, whose
bottom is a nitrocellulose or PVDF membrane coated with
a primary anticytokine antibody. The secreted cytokine is
captured by the solid phase antibody in the proximity of
the producing T-cell. Thus, antigen speciﬁc T cells can be
revealedasaspotbyasecondbiotinylatedantibody,followed
by a streptavidin-enzyme conjugate and the appropriate
substrate that is enzymatically cleaved so to generate an
insoluble product [94] .S p o t st h a tf o r ma r ee v e n t u a l l y
enumerated by visual inspection under low magniﬁcation.6 Journal of Biomedicine and Biotechnology
This assay requires simple instrumentation and thus it is
broadly used. The development of dedicated scanners for
spot identiﬁcation and enumeration of positive cells made
it applicable to large-scale screening. A further improvement
is the simultaneous analysis of two cytokines produced by a
single cell using two detection reagents labeled with diﬀerent
ﬂuorochromes [95]. This enables enumeration of single or
double producing T cells. Two limitations of ELIspot are
represented by the fact that T-cell phenotype cannot be
deﬁned,unlessseparatedsubsetsareused,andthattheactual
number of secreting cells can be underestimated. In fact,
if more than one speciﬁc T-cell interacts with the same
APC, one spot may contain more than one speciﬁc cell. The
384 well format can be proposed for ELIspot thanks to the
availability of appropriate scanners.
5.6. Intracytoplasmic Cytokine Staining (ICS). In this tech-
nique T cells are stimulated with antigen and APC. Respond-
ing speciﬁc T cells synthesize cytokines that are retained
in the cytoplasm because of the addition of drugs that
inhibitsecretion.Intracytoplasmiccytokinesarestainedwith
ﬂuorescent antibodies after cell permeabilization with a
detergent. This technique, developed in the late ‘90s [96]
proved very reliable and informative [21, 97]. The main
advantage of ICS is that numerous phenotypic markers
can be tested on speciﬁc T cells and diﬀerent cytokines
can be detected in a single cell using monoclonals labeled
with diﬀerent colors, the only limit being on the ﬂow
cytometer used for the analysis (and on the proﬁciency of
the ﬂow cytometrist). Thus, multiparametric and polychro-
matic ﬂow cytometry identiﬁes antigen speciﬁc T cells and
simultaneously evaluates diﬀerent eﬀector functions [98–
100]. The assay can be run in round bottom 96 well plates,
in combination with automatic samplers that feed the ﬂow
cytometer.Intheperspectiveoffurtherextendingtheassayto
the 384 well plate format, HTP-ICS analysis may be foreseen
in the near future. Limitations of ICS are represented by the
cost of reagents and instrumentation, by the fact that cells
are cultured under non-physiological conditions with an
inhibitor of protein secretion and by the fact that synthesized
cytokines cannot be quantitated. The analysis of mean
ﬂuorescence intensity for the stained cytokines, though,
may provide some indications for a relative semiquantitative
evaluation.
5.7. Cytokine Secretion and Cell Surface Capture (CSC). In
this assay, T cells are activated using culture conditions in
larger volumes (tubes, 24 well plates, ﬂasks). After 18–36
hours stimulation, cytokine secreting T cells are identiﬁed
with an anti-CD45 antibody conjugated with an anticy-
tokine antibody. During a short additional incubation step,
secreted cytokines are captured by the bispeciﬁc antibody
that decorates all PBMC. The cytokine captured on the
membrane of the producing T-cell is revealed by a second
antibody speciﬁc for the same cytokine, that is, directly or
indirectly ﬂuorescent for ﬂow cytometric analysis or sorting.
Alternatively, the second antibody can be recognized by
magnetic beads for preparative separation of speciﬁc T cells
on magnetic columns [101]. CSC is convenient for ex vivo
selection of speciﬁc T lymphocytes and it has been used
for selection of virus speciﬁc T cells [102, 103] that can be
subsequently reinfused for adoptive immunoreconstitution
[104, 105]. Cytokine positive cells can also be stained with
additional markers for extensive phenotyping, but since
numerous staining steps are needed, this system is not
advisable for screening of peptide panels.
5.8. Cytokine Secretion and Well Surface Capture (Cell-
ELISA). h a sb e e nr e p o r t e di n9 6w e l lp l a t e s[ 106]a n d
recently proposed, as a variation on the theme of ELIspot
and ELISA, in 384 or 1536 well plates [107, 108]. Secreted
cytokines, as readout of T-cell activation, can be tested in
culture supernatants by conventional ELISA. This procedure
can be simpliﬁed and miniaturized using cell-ELISA, an
assay in which wells are coated with the ﬁrst anticytokine
antibody. Medium and antigens are dispensed automatically
and the plates are frozen for later use. When needed, plates
are thawed and seeded with PBMC. During the 18–36
hours incubation, speciﬁc T cells responding to antigens
or peptides secrete the tested cytokine that is captured by
the solid phase antibody. Plates are eventually frozen before
ﬁnal processing. For development, plates are processed
following a conventional miniaturized ELISA protocol for a
quantitativeevaluationofproducedcytokinesusingstandard
c u r v e s .B e f o r ed e v e l o p m e n t ,c u l t u r es u p e r n a t a n t sc a nb e
saved for cytokine proﬁling using diﬀerent HTP approaches,
like multiparametric ﬂow cytometric assays or microarrays.
Major advantages of this method are that an HTP approach
can be taken for handling the multiwell plates.
In addition, secreted cytokines are quantitated and the
1536 well plate format permits the use of as few as 104
PBMC per tested antigen. This implies some considerations
regarding the frequency of antigen speciﬁc T cells. In fact,
as shown in Figure 3, a reasonable frequency of memory
T cells speciﬁc for a recall antigen can range between 0.1%
a n d1 % .L o w e rf r e q u e n c i e ss h o u l db ee x p e c t e df o rTc e l l s
speciﬁc for a single epitope. Therefore, each culture well
should contain a suﬃcient number of speciﬁc cells that
results in a positive signal. Sensitivity of cell-ELISA has
been estimated around 0.01% speciﬁc T cells diluted into
autologous non speciﬁc T cells by using established lines as
standards or PBMC with known frequencies of speciﬁc cells
[107]. This sensitivity range is similar, if not higher, than
other conventional methods including MM, ICS, ELIspot,
lymphoproliferation. Therefore, in order to be conﬁdent that
a detectable number of antigen speciﬁc T cells is seeded in
each well, we estimate that 104 PBMC per well is the lowest
threshold. This consideration applies to scaling down of all
types of lymphocyte based assays for evaluation of memory
responses. An intermediate format that proved convenient
was the 384 small well plate, in which each well has a culture
volume of 20uL instead of 40uL. Therefore, 2 × 104 PBMC
can be seeded instead of 4×104, leaving the same cell density
at the bottom of the culture well.
This obvious limitation due to reduction of the number
of tested T cells applies to all assays, even if positive
cells can be tested individually in principle. The issue of
background noise should be considered, since it is possibleJournal of Biomedicine and Biotechnology 7
< 0.01% > 1%
10/1000 T cells 1/1000 T cells
Low frequency
Naive repertoire
High frequency
Memory repertoire
Non speciﬁc cell
Speciﬁc cell
1% 0.1%
Figure 3: Frequency of speciﬁc T cells and culture size. The frequency of antigen speciﬁc T cells must be kept in mind when scaling down
culture conditions. Reasonable frequencies for speciﬁc T cells approximately range from >1% to <0.1% for memory responses to recall
protein antigens. Responses to individual epitopes may be at lower frequencies. Frequencies of speciﬁc T cells in the na¨ ıve repertoire may be
<0.01%. Panels represent 1000 lymphocytes containing 1 speciﬁc cell (0.1%, left panel) or 10 speciﬁc cells (1%, right panel). In case 1000
cells containing 1 speciﬁc cell are seeded in a microwell, the speciﬁc T-cell may or may not be dispensed according to Poissonian distribution
and the signal provided by one single cell may not be detected. In case 1000 cells containing 1% speciﬁc cells are seeded, 10 speciﬁc cells
can provide a detectable positive signal. Therefore, it can be assumed that the smallest number of cells per well should be >103 cells. This
reasoning applies to any T-cell assay adapted to 384 or 1536 well plates. Obviously, for very low frequency responses, more cells need to
be seeded, but in this case the intrinsic sensitivity of the assay should be checked to establish a frequency threshold. Unfortunately, reliable
cellular standards are not available, unless established antigen speciﬁc T-cell lines are used, as discussed in [108].
to detect ex vivo activated T cells in most lymphocyte
samples from healthy subjects, with remarkable variability.
Therefore, HTP techniques conﬂict with low frequencies
of responding cells. In case a na¨ ı v er e p e r t o i r en e e d st ob e
analyzed, one possibility can be to go through a preliminary
expansion phase with a pool of peptides and then screen
the expanded population at a later stage. This obviously
requires a second sample of autologous APC, that can be
PBMC or EBV transformed B cells for both CD4 and CD8
responses. The generation of antigen speciﬁc human T-cell
lines from a na¨ ıve repertoire for epitope mapping has long
been known [109, 110], but a recent appealing technique
has opened new perspectives. This “artiﬁcial lymph node”
technique, described as lymphoid tissue equivalent module,
permits T-cell priming in vitro under optimal conditions
(www.vaxdesign.com/). This is relevant in human studies, in
which antigens cannot be used in vivo for priming like in
animal studies. Nevertheless, studies using this approach and
evaluation of the system have not yet been published.
After collection of supernatants for cytokine testing, T
cells can be saved from wells in which cytokine production
was detected for further expansion to generate established
T-cell lines. An additional advantage of cell-ELISA is that it
can be applied in large scale, collaborative studies. In fact,
batches of plates containing predispensed antigen panels can
be prepared in the central laboratory and distributed to
peripheral laboratories. Here plates are thawed and seeded
with PBMC. After incubation, the plates are frozen again
and shipped back to the central laboratory for development.
This permits the design of multicenter studies on epitope
mapping in patients or vaccinees, for whom evaluation of
speciﬁc cellular immunity would not be feasible with other
methods. Simpliﬁed culture conditions including HEPES
buﬀer, that avoids the use of a CO2 atmosphere , and a
water bath or heating block in place of an incubator, in
addition to the possibility of using dry plates for easier
storage and shipment, make the assay appealing for use in
collaborativestudiesinresourcepoorsettings.Arecentstudy
validated cell-ELISA demonstrating its reproducibility [111].
The possibility of using frozen PBMC and whole blood was
also demonstrated. It should be noted that the phenotype
of responding cells cannot be deﬁned, unless puriﬁed CD4
and CD8 subsets are tested [107] and that the frequency of
antigen speciﬁc T cells cannot be determined by cell-ELISA.
Nevertheless, the number of speciﬁc T cells can be indirectly
inferred by the amount of secreted IFNg, that has been
estimated to be in the range of 1–3pg per antigen speciﬁc
cell during a 24 hours culture (Li Pira et al. ms in prep).8 Journal of Biomedicine and Biotechnology
6. Conclusions
T-cell epitope mapping allows to identify immunodominant
regions on antigenic proteins. Most assays require functional
T lymphocytes. Since extended peptide panels are generally
tested, large amounts of PBMC are required. Therefore,
eﬀorts have been made to reduce the size of culture
conditions, independently of the assay selected to deﬁne
antigen speciﬁc responses. The HTP approach is based on
miniaturized formats, now available as 384 and 1536 well
plates, that require automation to dispense peptides and cells
and for ﬁnal processing. Also dedicated scanners are needed
to scan these plates. Several assays described in this review
can be adapted to 384 well plates, like ICS and ELIspot, but
only cell-ELISA was demonstrated to be feasible in 1536 well
plates. This resulted in miniaturized cultures that contained
104 PBMC per well. This ﬁgure may represent the lowest
scaling down threshold that still grants the presence of a
detectable number of speciﬁc T cells, considering reasonable
concentrations of speciﬁc memory T cells around 0.1% or
less.
Miniaturized assays described here can be considered
for two main applications. The ﬁrst one is HTP epitope
mapping,thatis,testingextendedpeptidepanelswithPBMC
obtained from reasonable blood samples. The second one
is analysis of speciﬁc cellular immunity, that is, testing T-
cell responses towards a limited array of antigen prepara-
tions (proteins or peptide libraries) using PBMC obtained
from small blood samples. It should be noted that many
of the assays described here can also be scaled up for
preparative purposes to purify virus speciﬁc T cells for
adoptive immunoreconstitution, as recently reviewed [112].
In conclusion, T-cell epitope mapping is relevant for vaccine
development, for dissection of the quality of response in
vaccinees or in infected subjects and for deﬁnition of peptide
libraries as screening tools of cellular immunity. Thus, we
foresee continuous improvements in miniaturization and
automation of assays to provide an increasing amount of
peptide sequence information to be deposited in dedicated
databases.
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